More tools:Markets·Screener·Research·Chat

Repligen Corp (RGEN) Financial Statements

Repligen Corp
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S5VNT9
XNAS · usd
168.01▼ 0.52 (-0.31%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close168.53
Day's Range166.32 – 172.95
52-Week Range100.99 – 188.73
Volume779.4K
Avg Volume1.1M
Share Statistics
Shares Outstanding
Employees2,000
ExchangeXNAS
Listed1986-04-29
Share count as of July 24, 2026
Loading Income Statement…
Key questions about Repligen Corp (RGEN)
What is Repligen Corp's Market Cap?
Repligen Corp's Market Cap is $9.5B, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Enterprise Value?
Repligen Corp's Enterprise Value is $9.2B, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Trailing P/E?
Repligen Corp's Trailing P/E is 228.3×, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Price / Sales?
Repligen Corp's Price / Sales is 12.1×, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's EV / Revenue?
Repligen Corp's EV / Revenue is 11.7×, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's EV / EBITDA?
Repligen Corp's EV / EBITDA is 64.5×, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Revenue (TTM)?
Repligen Corp's Revenue (TTM) is $785.1M, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Net Income (TTM)?
Repligen Corp's Net Income (TTM) is $41.5M, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's EBITDA?
Repligen Corp's EBITDA is $143.4M, based on as-reported figures from SEC (XBRL) filings.
What is Repligen Corp's Diluted EPS (TTM)?
Repligen Corp's Diluted EPS (TTM) is 0.74, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Revenue
YoY growth+11.9%+14.8%+18.1%+21.9%
Costs and operating expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Restructuring activities and other charges——
Change in fair value of contingent consideration
Total costs and operating expenses
% of revenue93.2%91.8%91.0%91.1%
Income from operations
% of revenue6.8%8.2%9.0%8.9%
Other income (expense), net:
Investment income
Interest expense
Loss on sale of business——
Other (expense) income, net—
Other income (expense), net
Income before income taxes
Income tax provision
Net income
% of revenue2.5%4.3%6.7%7.9%
Basic—
Diluted—